de92b16c-4549-4025-9885-76c260c30cf7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- MITOTIC_SPINDLE+0.300
- PROTEIN_SECRETION+0.300
- SPERMATOGENESIS+0.300
- ANDROGEN_RESPONSE+0.100
- ANGIOGENESIS+0.100
- MYC_TARGETS_V1+0.100
- MYC_TARGETS_V2+0.100
- BILE_ACID_METABOLISM+0.000
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- COMPLEMENT-0.300
- HYPOXIA-0.300
- IL2_STAT5_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031372_D1.RNA-Seq | EPN | Supratentorial EPN | 0.868 |
| 2 | SRR12475132 | — | — | 0.867 |
| 3 | SRR975565 | — | — | 0.858 |
| 4 | TCGA-E9-A228-01A-31R-A157-07 | — | B | 0.857 |
| 5 | SAMN03290918 | — | — | 0.854 |
| 6 | 74d58c33-0c42-47bc-a55b-f56835480fbe | — | — | 0.854 |
| 7 | MDT-AP-3021 | Med | Medulloblastoma | 0.851 |
| 8 | BS_6NRTJSYK | Embryonal tumors | — | 0.847 |
| 9 | TCGA-4Z-AA7R-01A-11R-A39I-07 | — | — | 0.847 |
| 10 | BS_NKRYMHEP | medulloblastoma | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |